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Abstract
Background: Fluralaner is a novel systemic ectoparasiticide for dogs providing immediate and persistent flea, tick
and mite control after a single oral dose. Ivermectin has been used in dogs for heartworm prevention and at off
label doses for mite and worm infestations. Ivermectin pharmacokinetics can be influenced by substances affecting
the p-glycoprotein transporter, potentially increasing the risk of ivermectin neurotoxicity. This study investigated
ivermectin blood plasma pharmacokinetics following concurrent administration with fluralaner.
Findings: Ten Beagle dogs each received a single oral administration of either 56 mg fluralaner (Bravecto™), 0.3 mg
ivermectin or 56 mg fluralaner plus 0.3 mg ivermectin/kg body weight. Blood plasma samples were collected at
multiple post-treatment time points over a 12-week period for fluralaner and ivermectin plasma concentration
analysis.
Ivermectin blood plasma concentration profile and pharmacokinetic parameters Cmax, tmax, AUC∞ and t½ were
similar in dogs administered ivermectin only and in dogs administered ivermectin concurrently with fluralaner, and the
same was true for fluralaner pharmacokinetic parameters.
Conclusions: Concurrent administration of fluralaner and ivermectin does not alter the pharmacokinetics of either
compound. Based on the plasma pharmacokinetic profile and the clinical observations, there is no evident interaction
between fluralaner and ivermectin, and co-administration does not increase the risk of ivermectin associated
neurotoxicity.
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Background
Fluralaner is a novel systemically administered isoxazo-
line class compound that provides immediate and per-
sistent insecticidal and acaricidal efficacy after oral
administration to dogs. A field study has shown that a
single fluralaner dose administered orally to dogs pro-
vides at least 12 weeks of flea and tick control [1] and
another study demonstrated efficacy against mites
(Demodex spp.) [2]. Fluralaner was shown to be safe
when administered orally at overdoses of up to 5 times
the maximum clinical dose at 8-week intervals in healthy
Beagle dogs [3] and at overdoses of 3 times the max-
imum clinical dose in Collies bearing a homozygous de-
fect of the multi-drug-resistance 1 gene (MDR1 −/−) [4].
There are no known interactions of fluralaner with
other veterinary medicinal drugs [5] and fluralaner was
shown to be safe when administered concurrently with
macrocyclic lactones like milbemycin oxime [6] and
moxidectin [7].
Ivermectin is registered for the use in dogs at monthly
oral doses of 6 mcg/kg BW for heartworm protection
[8]; some veterinarians may choose to administer iver-
mectin at higher off label doses to treat dogs for differ-
ent worm or mite infestations (for example 0.05 mg/kg
for hookworm, 0.1 mg/kg BW for whipworms, 0.2 mg/
kg for Toxocara canis, 0.2-0.4 mg/kg for sarcoptic
mange, 0.2 mg/kg for nasal mites Pneumonyssus cani-
num, 0.3 mg/kg for cheyletiellosis, 0.3–0.6 mg/kg for
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demodicosis; orally or subcutaneous as single or re-
peated treatments) [9–20]; however, such high doses of
ivermectin cannot safely be administered to “ivermec-
tin-sensitive” dogs carrying a MDR1 mutation [21, 22].
Ivermectin is a substrate for the p-glycoprotein (p-gp)
transporter encoded by the MDR1 gene [22, 23]. This
transporter limits the entry of its substrates into the
body by an efflux-based mechanism, particularly at the
blood–brain barrier [24]. Dogs with a homozygous
defect of the MDR1 gene do not carry a functional p-
glycoprotein transporter and are therefore more sus-
ceptible to neurotoxicity caused by ivermectin [21].
Furthermore, drug-drug interactions at the p-glycoprotein
transporter may occur following the concurrent use of
ivermectin and drugs, leading to an increased risk of
neurotoxicity of ivermectin in MDR1 intact dogs. One
example is spinosad that inhibits the p-glycoprotein
transporter-mediated elimination of ivermectin in MDR1
intact dogs, thereby increasing ivermectin blood concen-
trations, which leads to a higher risk of neurotoxicity
when administering high off-label doses of ivermectin
concurrently with spinosad [25–30].
Veterinarians may choose to administer fluralaner and
ivermectin concurrently. To ensure that the concurrent
use does not increase the risk of ivermectin-associated
neurotoxicity, the pharmacokinetic profile of ivermectin
was investigated when administered concurrently with
fluralaner. For pharmacokinetic characterization over
time, fluralaner and ivermectin were administered at
high dose rates (i.e. 56 mg fluralaner/kg BW, the highest
expected dose in clinical use, and 0.3 mg ivermectin/
kg BW) and on a single occasion.
Table 1 Study groups for evaluation of the pharmacokinetic
profile of ivermectin and fluralaner when administered
concurrently to dogs








Gender Male 5 5 5
Female 5 5 5
Body weight
(kg)






































Ivermectin Ivermectin plus fluralaner
Fig. 1 Mean ivermectin plasma concentration (± standard deviation) in dogs following oral administration (0.3 mg/kg BW) alone or concurrently
with fluralaner (56 mg/kg BW)
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Methods
Thirty healthy Beagle dogs (15 males and 15 females)
were included in the study. Dogs were kept indoors in
pens with sealed floors and were housed in groups of
two or three, with the exception of the 3 days after
ivermectin/fluralaner administration, when dogs were
housed individually. Dogs had access to water ad libitum
throughout the study period and were fed a standard
dog diet.
This study was conducted in Ireland in compliance
with Directive 2010/63/EU S.I. No. 543 of 2012 and the
Irish national animal protection legislation framework
(experimental license no. B100\4500), and the study plan
was approved by the research organization institutional
(Charles River Laboratories Preclinical Services Ireland
Ltd.) ethics committee.
The 30 dogs were allocated to three study groups by
sorting within gender according to descending body
weight and random allocation to a group (Table 1). Iver-
mectin (Ivomec Classic Injection for Cattle and Sheep;
Merial Animal Health) was administered orally at a dose








































Fluralaner Fluralaner plus ivermectin
Fig. 2 Mean fluralaner plasma concentration (± standard deviation) in dogs following oral administration (56 mg/kg BW) alone or concurrently
with ivermectin (0.3 mg/kg BW)
Table 2 Ivermectin pharmacokinetic parameters in dogs following
oral administration (0.3 mg/kg BW) alone or concurrently with
fluralaner (56 mg/kg BW)
Parameter Unit Ivermectin Ivermectin
plus Fluralaner
P-value
Mean ± SD Mean ± SD
Cmax (ng/mL) 92.70 ± 26.77 80.52 ± 21.41 0.2465
tmax (day) 0.29 ± 0.10 0.31 ± 0.11 0.7269
AUC∞ (day*ng/mL) 141.96 ± 27.23 134.26 ± 37.99 0.5073
t½ (days) 2.07 ± 0.71 1.84 ± 0.42 0.4888
SD standard deviation
Table 3 Fluralaner pharmacokinetic parameters in dogs following
oral administration (56 mg/kg BW) alone or concurrently with
ivermectin (0.3 mg/kg BW)
Parameter Unit Fluralaner Fluralaner
plus Ivermectin
P-value
Mean ± SD Mean ± SD
Cmax (ng/mL) 7976 ± 4239 9312 ± 1767 0.1529
tmax (day) 3.00 ± 1.49 3.20 ± 2.66 0.8379
AUC∞ (day*ng/mL) 175778 ± 75122 184030 ± 49524 0.5373
t½ (days) 14.27 ± 2.53 13.45 ± 1.68 0.5107
SD standard deviation
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Animal Health) was administered orally at the maximum
clinical dose of 56 mg/kg BW on study day 0. Blood
samples for plasma concentration determination were
collected prior to administration and at 1, 2, 4, 6, 8, 10,
24, 48, 72, 120, 168, 240, 336, 504, 672, 1008, 1344, 1656
and 2016 h (84 days) after administration. Ivermectin
and fluralaner blood plasma concentrations were deter-
mined using validated methods (lower limit of quantifi-
cation 1 ng ivermectin/mL and 10 ng fluralaner/mL).
Standard pharmacokinetic parameters including max-
imum plasma concentration (Cmax), time to Cmax (tmax),
the extrapolated area under the curve (AUC∞) and the
elimination half-life (t½) were calculated using non-
compartmental and linear trapezoidal methods. Statistical
analysis of pharmacokinetic parameters was performed
after natural logarithmic transformation, with the excep-
tion of tmax, using ANOVA models and 90 % confidence
intervals, and the individual animal being the experimen-
tal unit. Pharmacokinetic and statistical analyses were per-
formed using SAS/STAT® (Language: Reference, Version
9.3, SAS Institute Inc., Cary, NC, USA).
Results and discussion
The plasma concentration versus time profile of ivermec-
tin was comparable in dogs administered ivermectin only
and in dogs administered ivermectin concurrently with
fluralaner (Fig. 1). Similarly, the plasma concentration
versus time profile of fluralaner was comparable in dogs
administered fluralaner only and in dogs administered
fluralaner concurrently with ivermectin (Fig. 2). The
pharmacokinetic parameters of both, ivermectin and
fluralaner, were also comparable across groups (Tables 2
and 3), with no statistical significant differences be-
tween groups.
Conclusions
Concurrent administration of fluralaner and ivermectin
does not alter the pharmacokinetics of either compound.
There is no evident interaction of fluralaner and ivermec-
tin indicating an increased risk of ivermectin-associated
neurotoxicity in fluralaner-treated dogs.
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